Christopher Pierce, EVP and Chief of Business Oper at Prelude Therapeutics Inc (PRLD), bought 3,750 shares at $19.00 ($71K) on 2020-09-29, disclosed to the SEC on 2020-09-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| PRLD | SELL | 2021-04-15 | $8K | — | Filing → |
| PRLD | SELL | 2021-04-09 | $33K | — | Filing → |